Key Insights

Highlights

Success Rate

68% trial completion

Published Results

11 trials with published results (37%)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 74/100

Termination Rate

30.0%

9 terminated out of 30 trials

Success Rate

67.9%

-18.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

58%

11 of 19 completed with results

Key Signals

11 with results68% success

Data Visualizations

Phase Distribution

29Total
Not Applicable (5)
Early P 1 (1)
P 1 (19)
P 2 (4)

Trial Status

Completed19
Terminated9
Withdrawn1
Active Not Recruiting1

Trial Success Rate

67.9%

Benchmark: 86.5%

Based on 19 completed trials

Clinical Trials (30)

Showing 20 of 20 trials
NCT00268385Phase 1Active Not Recruiting

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

NCT01165632Early Phase 1Completed

Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma

NCT02186509Phase 1Completed

Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas

NCT01051557Phase 1Completed

Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma

NCT01024907Phase 1Completed

Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas

NCT01635283Phase 2Completed

Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma

NCT00823459Phase 2Completed

Everolimus in Treating Patients With Recurrent Low-Grade Glioma

NCT00049127Phase 1Completed

Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor

NCT01977677Phase 1Completed

Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma

NCT01103375Phase 1Terminated

Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma

NCT01234805Not ApplicableTerminated

Yoga Therapy in Treating Patients With Malignant Brain Tumors

NCT01648348Phase 1Completed

Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme

NCT01234740Phase 1Completed

Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases

NCT01172964Phase 1Completed

A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas

NCT02194452Not ApplicableWithdrawn

Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors

NCT02967380Not ApplicableTerminated

Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases

NCT02175745Not ApplicableTerminated

18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas

NCT01148966Phase 1Terminated

Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors

NCT00499473Phase 2Completed

Sunitinib in Treating Patients With Recurrent Malignant Gliomas

NCT01119599Phase 1Completed

RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma

Scroll to load more

Research Network

Activity Timeline